Technology Available for Industry-Academia Collaboration or Technology Licensing. “A Potential COVID-19 Therapeutic Compound”(2020/4/16)

技術移轉

1. Title: NHRI technology, “A Potential COVID-19 Therapeutic Compound” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: The Technology is a novel compound which, in coronaviral infected cells, targets the RNP complex containing viral RNA and nucleoprotein to block viral replication and activities for anti-coronaviral mechanism….

Continue reading

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: a CXCR4-Targeted Antagonist”(2019/07/24)

產學合作

Title: NHRI technology, “DBPR807: a CXCR4-Targeted Antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: DBPR807 is a potent antagonist targeting CXCR4 receptors for medical treatment of peripheral blood stem cell transplantation, hepatocellular carcinoma and acute myocardial infarction. Potential collaboration partner qualifications: be incorporated and approved…

Continue reading

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR114: a multi-targeted kinase inhibitor for solid tumors”(2018/12/13)

Title: NHRI technology, “DBPR114: a multi-targeted kinase inhibitor for solid tumors” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: DBPR114 is a novel small molecule multi-target kinase inhibitor. Multi-target drugs can more effectively inhibit cancer cell proliferation, overcome drug resistance, and show better and broader anti-cancer…

Continue reading